Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun 10;16(1):266.
doi: 10.1186/s13023-021-01910-5.

Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden

Juan González-Moreno #  1   2 , Aina Gaya-Barroso #  2 , Inés Losada-López  1   2 , Adrián Rodríguez  1   2 , Teresa Bosch-Rovira  2   3 , Tomás Ripoll-Vera  2   4 , Mercedes Usón  2   5 , Antoni Figuerola  2   5 , Cristina Descals  2   5 , Carles Montalà  2   5 , María Asunción Ferrer-Nadal  2   6 , Eugenia Cisneros-Barroso  7   8
Affiliations
Multicenter Study

Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden

Juan González-Moreno et al. Orphanet J Rare Dis. .

Abstract

Background: Hereditary transthyretin (TTR) amyloidosis (ATTRv) is a heterogeneous disease with a clinical presentation that varies according to geographical area and TTR mutation. The symptoms of Val50Met-ATTRv are mainly neuropathic and progress to complete disability and death in most untreated patients within 10 to 15 years of diagnosis. The neurological effects may also be accompanied by gastrointestinal impairment, cardiomyopathy, nephropathy and/or ocular deposition. The disease is thus associated with a high degree of patient disability. Accordingly, we aimed to describe the psychosocial burden associated with ATTRv in a group of patients, asymptomatic Val50Met carriers, relatives and caregivers in the endemic focus of the disease in Majorca via a survey addressing various aspects related to psychosocial burden. We performed a an observational, descriptive, cross-sectional and multicentre study in order to analyze the prevalence of self-reported impact of ATTRv disease upon their daily life. In addition to the self-knowledge, fear and burden related to the disease. The survey was disseminated during the regular follow up at the outpatient clinic of the Hospital Universitario Son Llàtzer and during the meetings organized by the Andrade's Disease patients' advocacy group from the Balearic Islands. These meetings were attended also by subjects followed up by the Hospital Universitario Son Espases and their caregivers and relatives. Survey was self-administrated. No intervention was done by the investigators. 85 subjects completed the survey: 61 carrying the TTR-V50M variant and 24 caregivers or relatives.

Results: Our study revealed that, although most of the population studied had had prior contact with ATTRv through affected relatives, there was still a lack of information regarding disease diagnosis. Fear of the genetic test result and psychological issues were common in our population. Moreover, the disease had a stronger impact on the daily life of our patients than that of our asymptomatic carriers. Autonomic symptoms were the main source of burden for relatives and caregivers.

Conclusion: Our survey results show high psychosocial burden associated with Val50Met-ATTRv in our area.

Keywords: Burden of disease; Caregivers; Hereditary transthyretin amyloidosis; Rare disease; Well-being.

PubMed Disclaimer

Conflict of interest statement

None of the authors hold financial interests in the sponsoring organisation. The results described here do not contain any product specific names or literature from the sponsoring company. The authors declare no competing interests in relation to the work described here.

References

    1. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. doi: 10.1186/1750-1172-8-31. - DOI - PMC - PubMed
    1. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2003;10(3):160–184. - PubMed
    1. Munar-Qués M, Saraiva MJ, Viader-Farré C, Zabay-Becerril JM, Mulet-Ferrer J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain) Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2005;12(1):54–61. - PubMed
    1. Raya-Cruz M, Buades-Reines J, Gallego-Lezáun C, Ripoll-Vera T, Usón-Martín M. Clinical and analytical variability in cases of familial amyloidotic polyneuropathy (PAF-TTR): comparison between healthy carriers and symptomatic patients. Med Balear. 2015;30(3):31–36.
    1. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19. doi: 10.1186/2047-9158-3-19. - DOI - PMC - PubMed

Publication types

Supplementary concepts